Please enable JavaScript to continue using this application.

Compare $LCTX vs $TLSI | Chartloom

Compare

$LCTX vs $TLSI

Lineage Cell Therapeutics Inc · TriSalus Life Sciences Inc

LCTX

Lineage Cell Therapeutics Inc

TLSI

TriSalus Life Sciences Inc

Compare $LCTX vs $TLSI

Comparing Lineage Cell Therapeutics Inc and TriSalus Life Sciences Inc

LCTXLineage Cell Therapeutics Inc

TLSITriSalus Life Sciences Inc

LCTXLineage Cell Therapeutics Inc

Market cap

$248M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

28.49x

Rev growth (TTM)

-37.1%

YTD performance

-39.4%

52W performance

-42.5%

FCF yield

-10.0%

TLSITriSalus Life Sciences Inc

Market cap

$249M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.61x

Rev growth (TTM)

25.2%

YTD performance

-33.4%

52W performance

-16.3%

FCF yield

-9.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LCTX

TLSI

Detailed metrics comparison

LCTX

Lineage Cell Therapeutics Inc

TLSI

TriSalus Life Sciences Inc

Market Cap

LCTX$248M

TLSI$249M

Enterprise Value

LCTX$210M

TLSI$236M

Price

LCTX$0.99

TLSI$4.06

P/E Ratio

LCTXN/A

TLSIN/A

P/S Ratio

LCTX18.94x

TLSI5.53x

EV/Sales

LCTX16.09x

TLSI5.24x

EV/EBITDA

LCTX0.00x

TLSI0.00x

P/B Ratio

LCTX3.86x

TLSI40.61x

P/FCF Ratio

LCTXN/A

TLSIN/A

EV/FCF

LCTX-8.48x

TLSI-10.14x

PEG Ratio

LCTXN/A

TLSIN/A

Forward P/E (NTM)

LCTXN/A

TLSIN/A

Forward P/S (NTM)

LCTX28.49x

TLSI3.61x

Revenue (TTM)

LCTX$13M

TLSI$45M

Revenue Growth (YoY)

LCTX-37.1%

TLSI25.2%

Forward Rev Growth

LCTX-16.6%

TLSI40.1%

Gross Margin (TTM)

LCTX94.1%

TLSI85.8%

Operating Margin (TTM)

LCTX0.0%

TLSI0.0%

EBITDA Margin (TTM)

LCTX-199.6%

TLSI-66.4%

Net Margin (TTM)

LCTX-246.6%

TLSI-130.2%

FCF Margin (TTM)

LCTX-189.7%

TLSI-51.6%

Net Income (TTM)

LCTX$-32M

TLSI$-59M

FCF (TTM)

LCTX$-25M

TLSI$-23M

EPS (TTM)

LCTX-$0.13

TLSI-$1.01

ROE (TTM)

LCTX-7114.0%

TLSI-7902.0%

ROA (TTM)

LCTX-3087.0%

TLSI-5499.0%

ROIC (TTM)

LCTX-7104.0%

TLSI-1789.0%

Cash

LCTX$37M

TLSI$46M

Debt

LCTX$48K

TLSI$33M

Net Cash/Debt

LCTX$37M

TLSI$13M

Current Ratio (TTM)

LCTX6.61x

TLSI5.35x

Quick Ratio (TTM)

LCTX6.44x

TLSI4.72x

Debt/Equity (TTM)

LCTX0.00x

TLSI5.05x

Debt/Assets (TTM)

LCTX0.0%

TLSI0.0%

Interest Coverage (TTM)

LCTXN/A

TLSIN/A

Net Debt/EBITDA (TTM)

LCTX0.00x

TLSI0.00x

Beta

LCTX1.67

TLSI0.46

52W Performance

LCTX-42.5%

TLSI-16.3%

YTD Performance

LCTX-39.4%

TLSI-33.4%

% from 52W High

LCTX-52.4%

TLSI-48.9%

% from 52W Low

LCTX12.7%

TLSI84.5%

Asset Turnover (TTM)

LCTX0.07x

TLSI0.88x

FCF Yield (TTM)

LCTX-10.0%

TLSI-9.3%

Earnings Yield (TTM)

LCTX-13.0%

TLSI-23.5%

Dividend Yield (TTM)

LCTXN/A

TLSIN/A

Rule of 40

LCTX-226.8

TLSI-26.4

EV/GP/RG

LCTXN/A

TLSI0.11

Ticker research

View LCTX research View TLSI research

Metric	LCTX Lineage Cell Therapeutics Inc	TLSI TriSalus Life Sciences Inc
Market & Valuation
Market Cap	$248M	$249M
Enterprise Value	$210M	$236M
Price	$0.99	$4.06
P/E Ratio	N/A	N/A
P/S Ratio	18.94x	5.53x
EV/Sales	16.09x	5.24x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.86x	40.61x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.48x	-10.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	28.49x	3.61x
Revenue & Growth
Revenue (TTM)	$13M	$45M
Revenue Growth (YoY)	-37.1%	25.2%
Forward Rev Growth	-16.6%	40.1%
Profitability
Gross Margin (TTM)	94.1%	85.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-199.6%	-66.4%
Net Margin (TTM)	-246.6%	-130.2%
FCF Margin (TTM)	-189.7%	-51.6%
Net Income (TTM)	$-32M	$-59M
FCF (TTM)	$-25M	$-23M
EPS (TTM)	-$0.13	-$1.01
ROE (TTM)	-7114.0%	-7902.0%
ROA (TTM)	-3087.0%	-5499.0%
ROIC (TTM)	-7104.0%	-1789.0%
Financial Health
Cash	$37M	$46M
Debt	$48K	$33M
Net Cash/Debt	$37M	$13M
Current Ratio (TTM)	6.61x	5.35x
Quick Ratio (TTM)	6.44x	4.72x
Debt/Equity (TTM)	0.00x	5.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.67	0.46
52W Performance	-42.5%	-16.3%
YTD Performance	-39.4%	-33.4%
% from 52W High	-52.4%	-48.9%
% from 52W Low	12.7%	84.5%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.88x
FCF Yield (TTM)	-10.0%	-9.3%
Earnings Yield (TTM)	-13.0%	-23.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-226.8	-26.4
EV/GP/RG	N/A	0.11
Ticker research	View LCTX research	View TLSI research

Valuation

P/S Ratio

TLSI

5.53x

LCTX

18.94x

EV/FCF

TLSI

-10.14x

LCTX

-8.48x

Growth & revenue

Revenue Growth TTM

TLSI

25.2%

LCTX

-37.1%

Forward Revenue Growth

TLSI

40.1%

LCTX

-16.6%

Profitability & performance

Gross Margin

LCTX

94.1%

TLSI

85.8%

ROE

LCTX

-7114.0%

TLSI

-7902.0%

FCF Yield %

TLSI

-9.3%

LCTX

-10.0%

52-Week Performance

TLSI

-16.3%

LCTX

-42.5%

Detailed metrics comparison

LCTX

Lineage Cell Therapeutics Inc

TLSI

TriSalus Life Sciences Inc

Market Cap

LCTX$248M

TLSI$249M

Enterprise Value

LCTX$210M

TLSI$236M

Price

LCTX$0.99

TLSI$4.06

P/E Ratio

LCTXN/A

TLSIN/A

P/S Ratio

LCTX18.94x

TLSI5.53x

EV/Sales

LCTX16.09x

TLSI5.24x

EV/EBITDA

LCTX0.00x

TLSI0.00x

P/B Ratio

LCTX3.86x

TLSI40.61x

P/FCF Ratio

LCTXN/A

TLSIN/A

EV/FCF

LCTX-8.48x

TLSI-10.14x

PEG Ratio

LCTXN/A

TLSIN/A

Forward P/E (NTM)

LCTXN/A

TLSIN/A

Forward P/S (NTM)

LCTX28.49x

TLSI3.61x

Revenue (TTM)

LCTX$13M

TLSI$45M

Revenue Growth (YoY)

LCTX-37.1%

TLSI25.2%

Forward Rev Growth

LCTX-16.6%

TLSI40.1%

Gross Margin (TTM)

LCTX94.1%

TLSI85.8%

Operating Margin (TTM)

LCTX0.0%

TLSI0.0%

EBITDA Margin (TTM)

LCTX-199.6%

TLSI-66.4%

Net Margin (TTM)

LCTX-246.6%

TLSI-130.2%

FCF Margin (TTM)

LCTX-189.7%

TLSI-51.6%

Net Income (TTM)

LCTX$-32M

TLSI$-59M

FCF (TTM)

LCTX$-25M

TLSI$-23M

EPS (TTM)

LCTX-$0.13

TLSI-$1.01

ROE (TTM)

LCTX-7114.0%

TLSI-7902.0%

ROA (TTM)

LCTX-3087.0%

TLSI-5499.0%

ROIC (TTM)

LCTX-7104.0%

TLSI-1789.0%

Cash

LCTX$37M

TLSI$46M

Debt

LCTX$48K

TLSI$33M

Net Cash/Debt

LCTX$37M

TLSI$13M

Current Ratio (TTM)

LCTX6.61x

TLSI5.35x

Quick Ratio (TTM)

LCTX6.44x

TLSI4.72x

Debt/Equity (TTM)

LCTX0.00x

TLSI5.05x

Debt/Assets (TTM)

LCTX0.0%

TLSI0.0%

Interest Coverage (TTM)

LCTXN/A

TLSIN/A

Net Debt/EBITDA (TTM)

LCTX0.00x

TLSI0.00x

Beta

LCTX1.67

TLSI0.46

52W Performance

LCTX-42.5%

TLSI-16.3%

YTD Performance

LCTX-39.4%

TLSI-33.4%

% from 52W High

LCTX-52.4%

TLSI-48.9%

% from 52W Low

LCTX12.7%

TLSI84.5%

Asset Turnover (TTM)

LCTX0.07x

TLSI0.88x

FCF Yield (TTM)

LCTX-10.0%

TLSI-9.3%

Earnings Yield (TTM)

LCTX-13.0%

TLSI-23.5%

Dividend Yield (TTM)

LCTXN/A

TLSIN/A

Rule of 40

LCTX-226.8

TLSI-26.4

EV/GP/RG

LCTXN/A

TLSI0.11

Ticker research

View LCTX research View TLSI research

Metric	LCTX Lineage Cell Therapeutics Inc	TLSI TriSalus Life Sciences Inc
Market & Valuation
Market Cap	$248M	$249M
Enterprise Value	$210M	$236M
Price	$0.99	$4.06
P/E Ratio	N/A	N/A
P/S Ratio	18.94x	5.53x
EV/Sales	16.09x	5.24x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.86x	40.61x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.48x	-10.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	28.49x	3.61x
Revenue & Growth
Revenue (TTM)	$13M	$45M
Revenue Growth (YoY)	-37.1%	25.2%
Forward Rev Growth	-16.6%	40.1%
Profitability
Gross Margin (TTM)	94.1%	85.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-199.6%	-66.4%
Net Margin (TTM)	-246.6%	-130.2%
FCF Margin (TTM)	-189.7%	-51.6%
Net Income (TTM)	$-32M	$-59M
FCF (TTM)	$-25M	$-23M
EPS (TTM)	-$0.13	-$1.01
ROE (TTM)	-7114.0%	-7902.0%
ROA (TTM)	-3087.0%	-5499.0%
ROIC (TTM)	-7104.0%	-1789.0%
Financial Health
Cash	$37M	$46M
Debt	$48K	$33M
Net Cash/Debt	$37M	$13M
Current Ratio (TTM)	6.61x	5.35x
Quick Ratio (TTM)	6.44x	4.72x
Debt/Equity (TTM)	0.00x	5.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.67	0.46
52W Performance	-42.5%	-16.3%
YTD Performance	-39.4%	-33.4%
% from 52W High	-52.4%	-48.9%
% from 52W Low	12.7%	84.5%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.88x
FCF Yield (TTM)	-10.0%	-9.3%
Earnings Yield (TTM)	-13.0%	-23.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-226.8	-26.4
EV/GP/RG	N/A	0.11
Ticker research	View LCTX research	View TLSI research